
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health Co. has demonstrated a positive financial outlook with a 4Q23 revenue of $96.8 million, surpassing both prior estimates of $95.2 million and $88.0 million, primarily driven by strong performance in consumables. The average selling price (ASP) of total systems saw a notable increase of approximately 20% quarter-over-quarter, reaching $28.8K, which exceeded earlier estimates of $24.3K, attributed to a higher mix of direct sales. Despite the EBITDA guidance being back-end weighted, the overall trends in revenue growth and improved ASP indicate strong demand and operational efficiency, which may enhance the company’s growth trajectory moving forward.
Bears say
Beauty Health has reported a significant decline in core delivery system placements, which dropped over 30% year-over-year and quarter-over-quarter, falling well short of earlier estimates. This decrease raises concerns regarding future consumables sales, which are crucial for achieving the company's profitability goals in 2024, particularly as demand is essential for sustaining financial health. Furthermore, management's guidance for 1Q24 sales and adjusted EBITDA is notably below previous estimates, indicating potential challenges in meeting full-year financial targets and necessitating a substantial margin improvement in the latter half of the year.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares